Published in Mol Pharmacol on September 01, 2004
Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci (2011) 2.40
Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci (2010) 1.99
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res (2009) 1.93
Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev (2008) 1.83
Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol (2010) 1.51
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB J (2008) 1.39
Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci (2010) 1.20
Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol (2010) 1.12
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A (2012) 1.12
Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J (2010) 1.09
The blood-brain barrier: an engineering perspective. Front Neuroeng (2013) 1.09
Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab (2010) 1.06
Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats. Neurosci Lett (2006) 1.00
Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation (2012) 0.99
Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinology (2012) 0.98
Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J Am Chem Soc (2011) 0.96
Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers. J Neurosci (2014) 0.92
Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther (2010) 0.91
Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers Arch (2007) 0.89
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des (2014) 0.88
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
ABC transporter function and regulation at the blood-spinal cord barrier. J Cereb Blood Flow Metab (2012) 0.87
Endothelin-1 reduces p-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier. Cell Mol Neurobiol (2008) 0.87
Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J Cereb Blood Flow Metab (2012) 0.86
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res (2015) 0.85
Drug-induced trafficking of p-glycoprotein in human brain capillary endothelial cells as demonstrated by exposure to mitomycin C. PLoS One (2014) 0.82
Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity. J Neuroinflammation (2012) 0.82
Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides (2014) 0.81
Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. J Neurosci (2016) 0.81
The Changes of P-glycoprotein Activity by Interferon-γ and Tumor Necrosis Factor-α in Primary and Immortalized Human Brain Microvascular Endothelial Cells. Biomol Ther (Seoul) (2012) 0.81
Regulation of P-glycoprotein in renal proximal tubule epithelial cells by LPS and TNF-alpha. J Biomed Biotechnol (2010) 0.80
Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. J Cereb Blood Flow Metab (2011) 0.80
ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis. Brain Res (2014) 0.79
Cilostazol strengthens barrier integrity in brain endothelial cells. Cell Mol Neurobiol (2012) 0.79
Regulation of ABC transporters at the blood-brain barrier. Clin Pharmacol Ther (2015) 0.79
Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice. FASEB J (2012) 0.79
Uremic Toxins Induce ET-1 Release by Human Proximal Tubule Cells, which Regulates Organic Cation Uptake Time-Dependently. Cells (2015) 0.78
In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier. J Neurochem (2015) 0.78
Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling. Mol Pharmacol (2017) 0.75
Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier. ACS Chem Neurosci (2014) 0.75
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2005) 2.94
Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci (2011) 2.40
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol (2007) 1.97
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest (2002) 1.90
Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem (2002) 1.87
Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev (2008) 1.83
Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement (2011) 1.81
Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol (2006) 1.76
Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol (2004) 1.67
The outdoor air pollution and brain health workshop. Neurotoxicology (2012) 1.60
Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol (2005) 1.54
Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Reprod Sci (2007) 1.54
Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol (2010) 1.51
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement (2013) 1.51
Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm (2012) 1.51
In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol (2006) 1.51
Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology (2008) 1.47
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol (2011) 1.45
Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB J (2008) 1.39
Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol (2002) 1.35
Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res (2009) 1.35
Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev (2006) 1.33
Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J Cereb Blood Flow Metab (2008) 1.32
Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol (2005) 1.27
Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia (2007) 1.26
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem (2009) 1.25
Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci (2010) 1.20
Cloning and characterization of a novel apolipoprotein A-I binding protein, AI-BP, secreted by cells of the kidney proximal tubules in response to HDL or ApoA-I. Genomics (2002) 1.18
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res (2004) 1.18
Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood) (2005) 1.16
17-β-Estradiol: a powerful modulator of blood-brain barrier BCRP activity. J Cereb Blood Flow Metab (2010) 1.14
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A (2012) 1.12
Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol (2010) 1.12
MAC1 mediates LPS-induced production of superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity. Glia (2007) 1.11
Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke (2011) 1.09
Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J (2010) 1.09
Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab (2010) 1.06
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res (2008) 1.03
The role of A2E in prevention or enhancement of light damage in human retinal pigment epithelial cells. Photochem Photobiol (2002) 1.03
Scales as outcome measures for Alzheimer's disease. Alzheimers Dement (2009) 1.02
Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol (2008) 1.02
Choroid plexus epithelial monolayers--a cell culture model from porcine brain. Cerebrospinal Fluid Res (2006) 1.01
Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther (2009) 1.01
Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice. Am J Physiol Renal Physiol (2003) 0.99
Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab (2010) 0.98
Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol (2004) 0.97
Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J Am Chem Soc (2011) 0.96
MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J (2005) 0.96
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther (2009) 0.95
Modulation of drug transporters at the blood-brain barrier. Pharmacology (2004) 0.94
Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J Neuroinflammation (2011) 0.94
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology (2009) 0.94
The Clinical Global Impressions scale: errors in understanding and use. Compr Psychiatry (2008) 0.93
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol (2005) 0.93
Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol (2003) 0.93
Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis (2012) 0.93
Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv (2010) 0.92
Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol (2003) 0.92
Intracellular localization and subsequent redistribution of metal transporters in a rat choroid plexus model following exposure to manganese or iron. Toxicol Appl Pharmacol (2008) 0.92
Glutaric aciduria type I and methylmalonic aciduria: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus. Biochim Biophys Acta (2010) 0.92
Modulation of NK cell function by genetically coupled C-type lectin-like receptor/ligand pairs encoded in the human natural killer gene complex. Front Immunol (2013) 0.91
Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med (2007) 0.91
Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol (2002) 0.90
Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Res (2007) 0.90
Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos (2008) 0.90
Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol (2004) 0.89
Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol (2002) 0.89
Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. J Drug Target (2009) 0.89
Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor. FASEB J (2006) 0.89
Phototoxicity in human retinal pigment epithelial cells promoted by hypericin, a component of St. John's wort. Photochem Photobiol (2007) 0.88
Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm (2010) 0.88
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm (2008) 0.88
Revision of the criteria for Alzheimer’s disease: A symposium. Alzheimers Dement (2011) 0.88
Signaling pathways that regulate basal ABC transporter activity at the blood- brain barrier. Curr Pharm Des (2014) 0.88
In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci (2011) 0.87
The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3. Am J Physiol Regul Integr Comp Physiol (2006) 0.87
By-passing of P-glycoprotein using immunoliposomes. J Drug Target (2002) 0.87
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol (2010) 0.87